Yazar "Özyar, Enis" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Classical Kaposi's Sarcoma: efficacy of single high dose radiotherapy
    (PERGAMON-ELSEVIER SCIENCE LTD, 2005) Yıldız, Ferah; Genç, Mine; Cengiz, Mustafa; Özyar, Enis; Akbulut, S.; Hurmuz, P.; Atahan, I.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Pediatric and young adult (< 21) non-metastatic nasopharyngeal carcinoma (NPC) patients treated with neoadjuvant cisplatin and docetaxel (CD) chemoradiotherapy with plasma EBV DNA quantification
    (AMER SOC CLINICAL ONCOLOGY, 2008) Varan, Ali; Özyar, Enis; Gültekin, M.; Çorapcıoğlu, Funda; Köksal, Yavuz; Aydın, Burça; Akyüz, Canan; Büyükpamukçu, Münevver
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Pediatric and young adult (< 21) non-metastatic nasopharyngeal carcinoma patients treated with neoadjuvant cisplatin and docetaxel chemoradiotherapy with plasma EBV DNA quantification
    (WILEY-LISS, 2007) Varan, Ali; Özyar, Enis; Gültekin, Melis; Çorapcıoğlu, Funda; Köksal, Yavuz; Aydın, Burça; Akyüz, Canan
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    PEDIATRIC AND YOUNG ADULT NASOPHARYNGEAL CARCINOMA PATIENTS TREATED WITH PRERADIATION CISPLATIN AND DOCETAXEL CHEMOTHERAPY
    (ELSEVIER SCIENCE INC, 2009) Varan, Ali; Özyar, Enis; Çorapcıoğlu, Funda; Köksal, Yavuz; Aydın, Burca; Yazıcı, Nalan; Akyüz, Canan
    Purpose: To evaluate treatment results for pediatric and young adult (aged <21 years) patients with nonmetastatic nasopharyngeal carcinoma treated with neoadjuvant cisplatin + docetaxel and radiotherapy. Methods and Materials: Ten patients with nasopharyngeal carcinoma who received diagnoses between 2004 and 2007 were treated with four cycles of cisplatin 100 mg/m(2) + docetaxel 75 mg/m(2) on Day 1 with premedication every 3 weeks. All patients were treated with fractionated external beam radiotherapy after chemotherapy to a median dose of 59.4 Gy (range, 54-59.4 Gy) to the primary disease and 40 Gy to the supraclavicular field with the clavicles shielded. Five children were monitored with serum EBV DNA quantification at diagnosis, after each cycle of chemotherapy, before radiotherapy, and at follow-up. Results: The median age of the patients was 14 years (range, 9-20 years), with a male:female ratio of 6:4. Stage distribution was as follows: 2 patients had Stage Ilb disease, 2 had Stage III, 4 had Stage IVa, and 2 had Stage IVb disease. After cisplatin+docetaxel chemotherapy 1 patient had a complete response, 5 had a partial response, 3 had stable disease, and I had disease progression. The 2-year overall survival rate in our series was 90% and the event-free survival rate was 70%. No major chemotherapy toxicity was observed. The EBV DNA titers were higher in 2 of the 5 monitored patients at the time of diagnosis. Conclusion: As neoadjuvant chemotherapy before radiotherapy, the cisplatin+docetaxel combination is safe for use in the treatment of childhood nasopharyngeal carcinoma. (C) 2009 Elsevier Inc.
  • Küçük Resim Yok
    Öğe
    Radiotherapy in the management of Kaposi's sarcoma: Comparison of 8 Gy versus 6 Gy
    (NATL MED ASSOC, 2006) Yıldız, Ferah; Genç, Mine; Akyürek, Serap; Cengiz, Mustafa; Özyar, Enis; Selek, Uğur; Atahan, I. Lale
    Objective: To evaluate prospectively the efficacy of a single fraction of high-dose radiotherapy in patients with Kaposi's sarcoma. Patients: Between 1994 and 2004, 47 patients with Kaposi's sarcoma were treated at Hacettepe University, Department of Radiation Oncology. Thirteen (28%) patients received chemotherapy before radiotherapy and were referred due to recurrent or progressive disease or intolerance to chemotherapy. All lesions were treated locally with a 2-3-cm safety margin with 4-6-MeV electron beams. Radiotherapy consisted of a single fraction of 8 Gy in the first four years and 6 Gy thereafter. Results: The male:female ratio was 4:1. The median age was 61 years (range 18-87). Eight out of 47 patients (17%) had an underlying immunocompromised state, and one had a previous diagnosis of Hodgkin's disease. Of 203 fields treated, 51 and 152 fields were treated with 8 Gy and 6 Gy, respectively. Overall response rates (RR) at 12 months for 8- and 6 Gy were 93% and 86%, which were not statistically different. However, the difference between complete RRs at 12 months (93% and 60% for 8 Gy and 6 Gy respectively) was significant (p < 0.0001). Progression-free survival and reirradiation rates were not significantly different. Side effects were tolerable in all but three patients with grade 2-3 fibrosis and edema. Conclusion: Radiotherapy is an effective mode of treatment for Koposi's sarcoma, and a single dose of 8 Gy is more effective in terms of complete RR compared to 6 Gy, though overall response and progression-free survival rates were similar.